Document is current

Article History

Received: 17 September 2024

Revised: 11 February 2025

Accepted: 14 February 2025

First Online: 7 March 2025

Compliance with ethical standards

:

: The scientific guarantor of this publication is Jordi Rimola.

: The authors of this manuscript declare relationships with the following companies: B.S. is supported by a grant from Eu Commission. A.D. and A.F. reports lecture fees from Bayer, Boston Science, Gilead, and MSD, consultancy fees from Bayer, Astra Zeneca, Roche, SIRTEX, AB Exact Science, and Guerbert. A.G.-C., A.S., A.D., C.A., R.V., and J.B. has consulted for Arqule, Bayer-Shering Pharma, Novartis, BMS, BTG- Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, MSD, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano, Sanofi and UniversalDX; and received research/educational grants from Bayer, and lecture fees from Bayer-Shering Pharma, BTGBiocompatibles, Eisai, Terumo, Sirtex, Ipsen. M.R. reports consultancy from Bayer, BMS, Roche, Ipsen, Astra Zeneca, Boston Science, and Lilly; lecture fees from Bayer, BMS, Gilead, Lilly, Roche, and UniversalDX and travel support from Bayer, BMS, Lilly, and Astra Zeneca. Received research funding (to institution) from Bayer and Ipsen. J.R. has received consulting and/or speaking fees from Roche, Universal Dx, AstraZeneca, and travel grants from Bayer. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

: No complex statistical methods were necessary for this paper.

: Written informed consent was waived by the Institutional Review Board.

: Institutional Review Board approval was obtained (HCB/2019/1021).

: Some study subjects or cohorts have been previously reported in Darnell et al []. The results of the current and previous studies do not overlap.

: